

Takao Tamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2673347/publications.pdf>

Version: 2024-02-01

31
papers

2,845
citations

623734

14
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

3706
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	13.7	1,749
2	MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. <i>Pharmaceutical Research</i> , 2001, 18, 1400-1404.	3.5	288
3	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	5.3	155
4	CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. <i>Pharmaceutical Research</i> , 2001, 18, 721-727.	3.5	106
5	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	8.1	88
6	Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study. <i>Oncologist</i> , 2018, 23, 7-15.	3.7	82
7	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	5.3	61
8	A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). <i>Gastric Cancer</i> , 2019, 22, 344-354.	5.3	60
9	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	5.3	45
10	Omeprazole- and Esomeprazole-associated Hypomagnesaemia: Data Mining of the Public Version of the FDA Adverse Event Reporting System. <i>International Journal of Medical Sciences</i> , 2012, 9, 322-326.	2.5	35
11	Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS. <i>International Journal of Medical Sciences</i> , 2012, 9, 441-446.	2.5	33
12	A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. <i>International Journal of Clinical Oncology</i> , 2017, 22, 905-912.	2.2	33
13	Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGS1105, HERBIS-4A Trial. <i>Oncologist</i> , 2018, 23, 1411-e147.	3.7	15
14	Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e687-e697.	2.3	15
15	Effects of Bolus Injection of 5-Fluorouracil on Steady-State Plasma Concentrations of 5-Fluorouracil in Japanese Patients with Advanced Colorectal Cancer. <i>International Journal of Medical Sciences</i> , 2011, 8, 406-412.	2.5	13
16	Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 614-621.	2.2	13
17	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data.. <i>Journal of Clinical Oncology</i> , 2020, 38, 383-383.	1.6	10
18	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	5.3	9
20	A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. <i>International Journal of Surgery Case Reports</i> , 2020, 72, 471-476.	0.6	5
21	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 688709.	2.8	5
22	Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). <i>Frontiers in Oncology</i> , 2021, 11, 576036.	2.8	4
23	Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8-8.	1.6	3
24	Association between circadian and chemotherapeutic cycle effects on plasma concentration of 5- <i>fluorouracil</i> and the clinical outcome following definitive 5- <i>fluorouracil</i> /cisplatin-based chemoradiotherapy in patients with esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2018, 17, 668-675.	1.8	2
25	The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-679.	1.6	2
26	Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer: Multicenter retrospective study in Japan.. <i>Journal of Clinical Oncology</i> , 2020, 38, 377-377.	1.6	2
27	Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1871-1880.	2.2	1
28	CEA response at four weeks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab-based chemotherapy: A STEP-analysis in the JACCRO CC-05/06 trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, 543-543.	1.6	1
29	Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 2.	1.0	1
30	Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 102-102.	1.6	0
31	Comparing five-weekly S-1 plus cisplatin with tri-weekly capecitabine plus cisplatin in patients with HER2-negative recurrent gastric cancer after S-1 adjuvant therapy or chemotherapy naïve advanced gastric cancer: A pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 379-379.	1.6	0